Advertisement
Australia markets closed
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • AUD/USD

    0.6540
    +0.0017 (+0.26%)
     
  • OIL

    83.85
    +0.28 (+0.34%)
     
  • GOLD

    2,361.50
    +19.00 (+0.81%)
     
  • Bitcoin AUD

    98,573.48
    +935.08 (+0.96%)
     
  • CMC Crypto 200

    1,392.99
    -3.55 (-0.25%)
     
  • AUD/EUR

    0.6090
    +0.0017 (+0.28%)
     
  • AUD/NZD

    1.0979
    +0.0022 (+0.20%)
     
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     
  • FTSE

    8,114.52
    +35.66 (+0.44%)
     
  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     
  • DAX

    18,050.26
    +132.98 (+0.74%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Company News For Aug 6, 2019

  • Allergan plc’s AGN shares dipped 0.2% after the company reported second quarter 2019 earnings per share of $4.38, lower than $4.42 a share in the year ago quarter

  • Energizer Holdings, Inc.’s ENR shares lost 3.7% after the company reported third quarter fiscal 2019 earnings per share of $0.37, lower than the Zacks Consensus Estimate of $0.47

  • Shares of Edgewell Personal Care Company EPC lost 4.7% after the company reported third quarter fiscal 2019 revenues of $609 million, lower than the Zacks Consensus Estimate of $614 million

  • Shares of Mallinckrodt plc MNK fell 2.1% afterthe company reported second quarter 2019 revenues of $823 million, lower than the Zacks Consensus Estimate of $824 million


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Energizer Holdings, Inc. (ENR) : Free Stock Analysis Report
 
Edgewell Personal Care Company (EPC) : Free Stock Analysis Report
 
Allergan plc (AGN) : Free Stock Analysis Report
 
Mallinckrodt public limited company (MNK) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research